Show
Sort by
-
Long-term follow-up, up to 7 years, in the RESONATE-2 study of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL)
(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S316-S316 -
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
-
- Journal Article
- A1
- open access
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
-
Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study
-
Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial
-
Effect of dose modifications on response to duvelisib in patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO trial
-
Five-year follow-up after ibrutinib therapy for first-line treatment of chronic lymphocytic leukemia
-
- Journal Article
- A1
- open access
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : extended phase 3 results from RESONATE-2
-
The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
-
Results from the phase 3 DUOTM trial : a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma